Compagnie Lombard Odier SCmA Cuts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Compagnie Lombard Odier SCmA lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 10.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 134,810 shares of the medical device company’s stock after selling 16,473 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in DexCom were worth $10,484,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Geode Capital Management LLC boosted its position in shares of DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after acquiring an additional 214,136 shares during the last quarter. Jennison Associates LLC increased its stake in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after buying an additional 710,858 shares during the period. Groupama Asset Managment increased its stake in shares of DexCom by 1.1% during the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after buying an additional 31,358 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after buying an additional 876,739 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after purchasing an additional 288,381 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DXCM. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Canaccord Genuity Group raised their price target on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Royal Bank of Canada dropped their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Raymond James dropped their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $98.41.

DexCom Trading Up 0.3 %

Shares of DXCM stock opened at $84.09 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a fifty day moving average of $82.11 and a two-hundred day moving average of $75.19. The firm has a market capitalization of $32.85 billion, a PE ratio of 50.35, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. As a group, research analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Activity

In other news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,342 shares of company stock worth $3,628,069 over the last 90 days. 0.30% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.